Comparison of the efficacy of colistin monotherapy and colistin combination therapies in the treatment of nosocomial pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii
| Autor: | Gülbin Aygencel, Esra Kayacan, Dilek Karamanlioglu, Melda Turkoglu, Burcu Bilaloğlu, Murat Dizbay, İskender Kara, Fatma Yıldırım |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Combination therapy lcsh:Medicine Tigecycline Critical Care and Intensive Care Medicine Sepsis Internal medicine polycyclic compounds medicine Intensive care medicine biology Septic shock business.industry lcsh:R lcsh:Medical emergencies. Critical care. Intensive care. First aid Ventilator-associated pneumonia lcsh:RC86-88.9 biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification medicine.disease Acinetobacter baumannii Pneumonia Colistin bacteria business medicine.drug |
| Zdroj: | Southern African Journal of Critical Care, Vol 31, Iss 2, Pp 51-58 (2015) Southern African Journal of Critical Care; Vol 31, No 2 (2015); 51-58 Southern African Journal of Critical Care (Online), Volume: 31, Issue: 2, Pages: 51-58, Published: NOV 2015 |
| ISSN: | 2078-676X 1562-8264 |
| DOI: | 10.7196/sajcc.2015.v31i2.246 |
| Popis: | Objective. To investigate whether there was a difference in mortality, clinical response and bacterial eradication between colistin monotherapy and colistin combination therapies for the treatment of nosocomial pneumonia/ventilator-associated pneumonia (VAP) caused by Acinetobacter baumannii in a medical intensive care unit (ICU). Methods. This retrospective, observational and single-centre study included all patients who were in the medical ICU of Gazi University Medical Faculty Hospital and diagnosed with nosocomial pneumonia/VAP caused by A. baumannii between January 2009 and September 2014. Results. The median age of the 134 patients was 68 years and 53.3% were male. The most common causes of admission were respiratory insufficiency (66.7%) and sepsis/septic shock (54.8%). In patients with nosocomial pneumonia/VAP caused by A. baumannii , on median day 5 of admission, colistin monotherapy was used in 23 (21.6%) patients, a carbapenem combination was used in 80 (59.7%) patients, sulbactam-ampicillin combination was used in 42 (31.4%) patients, tigecycline combination was used in 26 (19.4%) patients, and sulbactam-cefoperazone combination was used in 17 (12.7%) patients. Median ICU stay of the patients was 15.5 days, and 112 (83.6%) patients died. Colistin monotherapy and combination therapies had no superiority over each other in clinical response for the treatment of A. baumannii -associated nosocomial pneumonia/VAP. Mortality was found to be higher in patients receiving the colistin-carbapenem combination (64.3% v. 36.4%, p =0.016). Discharge/day-of-death Sequential Organ Failure Assessment score (odds ratio (OR) 2.017, 95% confidence interval (CI) 1.330 - 3.061) and vasopressor use (OR 9.014, 95% CI 1.360 - 59.464) were independent risk factors for ICU mortality. Conclusion. Colistin monotherapy and combination therapies have no superiority over each other for clinical response in the treatment of nosocomial pneumonia/VAP caused by multidrug-resistant A. baumannii . Colistin-SAM was associated with improved microbiological eradication and colistin-carbapenem combination was associated with increased mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|